Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of YH22162 in Healthy Volunteers
NCT03662620Phase 1Completed
- Sponsor
- Yuhan
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + amlodipine + chlorthalidone in hypertension (HTN) (2 arms), sponsored by Yuhan. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration and Maximum Plasma Concentration. Started Oct 2018; status: completed.
02
Drugs
telmisartan + amlodipine + chlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03662620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662620.